# Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

> **NCT03990896** · PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT03990896
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-18
- **Primary completion:** 2027-03-31
- **Final completion:** 2028-04-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03990896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03990896, "Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03990896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*